---
title: "Celon Pharma Says FDA Deems Phase III Study Concept For CPL'36 Treatment Reasonable"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275925527.md"
datetime: "2026-02-13T16:18:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275925527.md)
  - [en](https://longbridge.com/en/news/275925527.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275925527.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275925527.md) | [繁體中文](https://longbridge.com/zh-HK/news/275925527.md)


# Celon Pharma Says FDA Deems Phase III Study Concept For CPL'36 Treatment Reasonable

Feb 13 (Reuters) - Celon Pharma SA (CLNP.WA) : \* ANNOUNCES COMPLETION OF ANALYSIS OF WRITTEN RESPONSES FROM FDA REGARDING CPL'36 FOR PARKINSON'S DISEASE-INDUCED DYSKINESIA (PD-LID) \* FDA DEEMS PROPOSED PHASE III STUDY CONCEPT FOR CPL'36, INCLUDING DESIGN, DURATION, AND PRIMARY ENDPOINT, AS REASONABLE \* BELIEVES FDA STANCE SUPPORTS CONTINUING PHASE III PROGRAM AND WILL INCORPORATE RECOMMENDATIONS INTO PROTOCOLS Source text: Further company coverage: (CLNP.WA)

## Related News & Research

- [Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call](https://longbridge.com/en/news/281187029.md)
- [Industrials Down on Energy-Shock Duration Fears - Industrials Roundup](https://longbridge.com/en/news/281578755.md)
- [ZAWYA: NYU Abu Dhabi and University of Denver Researchers identify promising small molecule inhibitor of brain disorders like parkinson’s disease](https://longbridge.com/en/news/281500635.md)
- [Vertex Pharmaceuticals Inc - FDA expands indication for trikafta in cf patients ages 2 and older](https://longbridge.com/en/news/281371049.md)
- [Ultragenyx BLA for UX111 Accepted for FDA Review](https://longbridge.com/en/news/281535872.md)